Pricing Log in Create free account

Adial Pharmaceuticals, Inc. (ADIL) vs IMMURON (IMRN)

Adial Pharmaceuticals, Inc. and IMMURON are both Biotechnology companies. Adial Pharmaceuticals, Inc. and IMMURON are of similar size ($8.3M and $8.3M). Adial Pharmaceuticals, Inc. has the higher net margin (0.00% vs −262.7%) and the higher return on invested capital (0.00% vs 0.00%). Across the 10 metrics below, Adial Pharmaceuticals, Inc. leads on 5 and IMMURON on 5.

Valuation

Metric ADIL IMRN Biotechnology median
P/E n/m n/m 8.50
P/S n/m n/m 9.71
P/B n/m n/m 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA 0.22 0.93 0.64
EV/Sales n/m (3.47) 9.21
Earnings yield (461.83%) (2.10%) (33.15%)
Free cash flow yield (68.29%) 0.00% (25.50%)

Profitability

Metric ADIL IMRN Biotechnology median
Gross margin 0.00% 71.28% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% (262.71%) 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity 352.60% 0.00% (56.36%)
Return on assets (322.10%) 0.00% (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric ADIL IMRN Biotechnology median
Revenue growth (TTM) — (6.62%) 6.02%
EPS growth (last fiscal year) 82.46% 37.29% 30.26%
Revenue growth, 5-year CAGR — 116.96% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ADIL IMRN Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 5.63 7.17 4.72
Net debt to EBITDA 0.75 1.81 0.96

Dividend

Metric ADIL IMRN Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric ADIL IMRN Biotechnology median
Market cap 8.25m 8.31m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack